Q: How low should my A1C go?

ADA default is < 7%. Tighter (< 6.5%) if achievable without hypoglycemia and life expectancy is long. Looser (< 8%) for older adults with limited life expectancy, severe hypo history, or extensive comorbidities. Individualize with your endocrinologist — not everyone benefits from aggressive targets.

Q: Can I use Wegovy or Zepbound for my diabetes?

Technically Wegovy and Zepbound are labeled for chronic weight management, not T2D. The active molecules work for glycemia, but payers usually require the T2D-labeled brand (Ozempic, Mounjaro) for diabetes indication. If you have both obesity and T2D, your clinician chooses the label based on payer and priorities.

Q: What if my A1C stops dropping?

First confirm adherence and therapeutic dose. Second, look for contributors: corticosteroids, new insulin resistance from weight regain, worsening beta-cell function. Third, consider adding an SGLT2 inhibitor for complementary mechanism and CV/renal benefit. Basal insulin is still reasonable if oral+GLP-1 combos aren't achieving target.

Q: Does GLP-1 cause pancreatitis?

Observational data are mixed. Pivotal trials and meta-analyses generally don't show a large signal. Current labels retain a precautionary note. Don't initiate in patients with a history of pancreatitis without specialist input, and discontinue if symptoms develop.

Q: What does FLOW mean for me if I have CKD?

FLOW (semaglutide 1 mg in T2D+CKD) showed 24% reduction in composite kidney outcome (≥50% eGFR loss, kidney failure, kidney or CV death) over 3.4 years. The trial stopped early for efficacy. KDIGO and ADA 2024–2025 guidelines now prefer semaglutide (alongside SGLT2i) in T2D+CKD. If eGFR 45 and albuminuria, dialysis deferral is a major expected-value benefit.

Q: How much should I expect insulin to come down?

When adding a GLP-1 to basal insulin, insulin typically needs 20–30% reduction to avoid hypoglycemia. When added to a sulfonylurea, halve or discontinue the SU. Your endocrinologist should monitor closely the first 4–8 weeks — hypoglycemia is the main preventable adverse event.

Q: What's the dose-response for A1C reduction?

Tirzepatide: 5 mg = −1.7 to −2.0 pp, 10 mg = −2.0 to −2.3 pp, 15 mg = −2.3 to −2.6 pp. Semaglutide: 1 mg = −1.5 to −1.8 pp, 2 mg = −1.9 to −2.1 pp. Dulaglutide: 1.5 mg = −1.2 to −1.5 pp, 4.5 mg = −1.7 to −1.9 pp. If your A1C is at target, escalation buys little; if > 1.5% above target, dose-up is supported.

Question 1

Will Ozempic replace my metformin?

Accepted Answer

Usually not. Metformin is inexpensive, well tolerated, and has its own outcomes data. Most endocrinologists continue metformin when adding a GLP-1. Discontinuing metformin is reasonable only if it causes GI side effects stacked on GLP-1 side effects, or if eGFR drops below 30.

Question 2

How low should my A1C go?

Accepted Answer

ADA default is < 7%. Tighter (< 6.5%) if achievable without hypoglycemia and life expectancy is long. Looser (< 8%) for older adults with limited life expectancy, severe hypo history, or extensive comorbidities. Individualize with your endocrinologist — not everyone benefits from aggressive targets.

Question 3

Can I use Wegovy or Zepbound for my diabetes?

Accepted Answer

Technically Wegovy and Zepbound are labeled for chronic weight management, not T2D. The active molecules work for glycemia, but payers usually require the T2D-labeled brand (Ozempic, Mounjaro) for diabetes indication. If you have both obesity and T2D, your clinician chooses the label based on payer and priorities.

Question 4

What if my A1C stops dropping?

Accepted Answer

First confirm adherence and therapeutic dose. Second, look for contributors: corticosteroids, new insulin resistance from weight regain, worsening beta-cell function. Third, consider adding an SGLT2 inhibitor for complementary mechanism and CV/renal benefit. Basal insulin is still reasonable if oral+GLP-1 combos aren't achieving target.

Question 5

Does GLP-1 cause pancreatitis?

Accepted Answer

Observational data are mixed. Pivotal trials and meta-analyses generally don't show a large signal. Current labels retain a precautionary note. Don't initiate in patients with a history of pancreatitis without specialist input, and discontinue if symptoms develop.

Question 6

What does FLOW mean for me if I have CKD?

Accepted Answer

FLOW (semaglutide 1 mg in T2D+CKD) showed 24% reduction in composite kidney outcome (≥50% eGFR loss, kidney failure, kidney or CV death) over 3.4 years. The trial stopped early for efficacy. KDIGO and ADA 2024–2025 guidelines now prefer semaglutide (alongside SGLT2i) in T2D+CKD. If eGFR 45 and albuminuria, dialysis deferral is a major expected-value benefit.

Question 7

How much should I expect insulin to come down?

Accepted Answer

When adding a GLP-1 to basal insulin, insulin typically needs 20–30% reduction to avoid hypoglycemia. When added to a sulfonylurea, halve or discontinue the SU. Your endocrinologist should monitor closely the first 4–8 weeks — hypoglycemia is the main preventable adverse event.

Question 8

What's the dose-response for A1C reduction?

Accepted Answer

Tirzepatide: 5 mg = −1.7 to −2.0 pp, 10 mg = −2.0 to −2.3 pp, 15 mg = −2.3 to −2.6 pp. Semaglutide: 1 mg = −1.5 to −1.8 pp, 2 mg = −1.9 to −2.1 pp. Dulaglutide: 1.5 mg = −1.2 to −1.5 pp, 4.5 mg = −1.7 to −1.9 pp. If your A1C is at target, escalation buys little; if > 1.5% above target, dose-up is supported.

GLP-1 A1C Reduction for T2D in 2026 — Ozempic, Mounjaro, Trulicity Projector

Your inputs

Results

GLP-1s redefined the second line of T2D therapy

The anchor trials

Expected A1C reduction by agent and dose

When to add, substitute, or combine

Safety notes

Frequently asked questions